This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.rt.com/news/513562-moderna-covid-vaccine-south-africa/
The article has changed 3 times. There is an RSS feed of changes available.
| Version 0 | Version 1 |
|---|---|
| Moderna working on new Covid-19 vaccine booster to tackle South Africa strain | Moderna working on new Covid-19 vaccine booster to tackle South Africa strain |
| (7 months later) | |
| US biotech firm Moderna said on Monday that it was starting trials for another Covid-19 vaccine to immunize people against a mutant strain of the virus recently discovered in South Africa. | US biotech firm Moderna said on Monday that it was starting trials for another Covid-19 vaccine to immunize people against a mutant strain of the virus recently discovered in South Africa. |
| The company also said laboratory tests had shown that two doses of its current Covid-19 shot are effective against the variant, known as 501.V2, as well as the B.1.1.7 strain of the virus found in Britain late last year. | The company also said laboratory tests had shown that two doses of its current Covid-19 shot are effective against the variant, known as 501.V2, as well as the B.1.1.7 strain of the virus found in Britain late last year. |
| Moderna did stress, however, that the immune response generated by the vaccine appeared to be six times weaker against the South African variant compared to the previous Covid-19 strain, although with antibody levels still above the threshold required for protection. | Moderna did stress, however, that the immune response generated by the vaccine appeared to be six times weaker against the South African variant compared to the previous Covid-19 strain, although with antibody levels still above the threshold required for protection. |
| The findings, which have not yet been peer-reviewed, are from a Moderna study in collaboration with the National Institute of Allergy and Infectious Diseases in the US. | The findings, which have not yet been peer-reviewed, are from a Moderna study in collaboration with the National Institute of Allergy and Infectious Diseases in the US. |
| Moderna CEO Stephane Bancel said in a statement that the company is trying to determine if its booster candidate will be more effective in creating blood antibodies against 501.V2 and “potentially future variants.” | Moderna CEO Stephane Bancel said in a statement that the company is trying to determine if its booster candidate will be more effective in creating blood antibodies against 501.V2 and “potentially future variants.” |
| The pharma firm's current Covid-19 vaccine is being rolled out in Europe, the US and elsewhere following its approval by local regulators. | The pharma firm's current Covid-19 vaccine is being rolled out in Europe, the US and elsewhere following its approval by local regulators. |
| The trials of the company's new booster are being carried out with the US National Institutes of Health, and will involve several thousand participants given either a second shot of the original vaccine or a booster shot. | The trials of the company's new booster are being carried out with the US National Institutes of Health, and will involve several thousand participants given either a second shot of the original vaccine or a booster shot. |
| Like Pfizer's Covid-19 jab, Moderna's uses technology known as RNA – or mRNA – which triggers an immune response by prompting cells to make a piece of spike protein, as opposed to traditional vaccines, which often use a weakened form of a virus. | Like Pfizer's Covid-19 jab, Moderna's uses technology known as RNA – or mRNA – which triggers an immune response by prompting cells to make a piece of spike protein, as opposed to traditional vaccines, which often use a weakened form of a virus. |
| The 501.V2 variant was discovered in South Africa last year and is more easily transmissible due to a mutation that allows it to bind more easily to human cells. | The 501.V2 variant was discovered in South Africa last year and is more easily transmissible due to a mutation that allows it to bind more easily to human cells. |
| British Health Secretary Matt Hancock said on Sunday that 77 cases of 501.V2 had been detected in the UK, although there was no evidence to suggest community transmission of the variant had taken place. | British Health Secretary Matt Hancock said on Sunday that 77 cases of 501.V2 had been detected in the UK, although there was no evidence to suggest community transmission of the variant had taken place. |
| Like this story? Share it with a friend! | Like this story? Share it with a friend! |
| Dear readers and commenters, | |
| We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system. | |
| Sorry for the inconvenience, and looking forward to your future comments, | |
| RT Team. |